EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults

Andrew W Lee, Ken Liu, Edouard Lhomme, Julie Blie, John McCullough, Matthew T Onorato, Laurie Connor, Jakub K Simon, Sheri Dubey, Susan VanRheenen, Jonathan Deutsch, Abigail Owens und 21 weitere

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciad693 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Andrew W Lee und 32 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc., Rahway, New Jersey, USA. Hauptthemen laut MEDLINE: Hemorrhagic Fever, Ebola, Ebola Vaccines, Ebolavirus. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ASPR HHS, National Institutes of Health, (NIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The rVSVΔG-ZEBOV-GP vaccine (ERVEBO®) is a single-dose, live-attenuated, recombinant vesicular stomatitis virus vaccine indicated for the prevention of Ebola virus disease (EVD) caused by Zaire ebolavirus in individuals 12 months of age and older.

Methods

The Partnership for Research on Ebola VACcination (PREVAC) is a multicenter, phase 2, randomized, double-blind, placebo-controlled trial of 3 vaccine strategies in healthy children (ages 1–17) and adults, with projected 5 years of follow-up (NCT02876328). Using validated assays (GP-ELISA and PRNT), we measured antibody responses after 1-dose rVSVΔG-ZEBOV-GP, 2-dose rVSVΔG-ZEBOV-GP (given on Day 0 and Day 56), or placebo. Furthermore, we quantified vaccine virus shedding in a subset of children's saliva using RT-PCR.

Results

In total, 819 children and 783 adults were randomized to receive rVSVΔG-ZEBOV-GP (1 or 2 doses) or placebo. A single dose of rVSVΔG-ZEBOV-GP increased antibody responses by Day 28 that were sustained through Month 12. A second dose of rVSVΔG-ZEBOV-GP given on Day 56 transiently boosted antibody concentrations. In vaccinated children, GP-ELISA titers were superior to placebo and non-inferior to vaccinated adults. Vaccine virus shedding was observed in 31.7% of children, peaking by Day 7, with no shedding observed after Day 28 post-dose 1 or any time post-dose 2.

Conclusions

A single dose of rVSVΔG-ZEBOV-GP induced robust antibody responses in children that was non-inferior to the responses induced in vaccinated adults. Vaccine virus shedding in children was time-limited and only observed after the first dose. Overall, these data support the use of rVSVΔG-ZEBOV-GP for the prevention of EVD in at-risk children. Clinical Trials Registration. The study is registered at ClinicalTrials.gov (NCT02876328), the Pan African Clinical Trials Registry (PACTR201712002760250), and the European Clinical Trials Register (EudraCT number: 2017-001798-18).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemorrhagic Fever, EbolaEbola VaccinesEbolavirusAdultChildHumansAntibodies, ViralViral Envelope ProteinsVaccines, SyntheticVaccinationVaccines, AttenuatedImmunogenicity, Vaccine

Stichwörter der Autor:innen

Ebolaimmunogenicitypediatricsvaccinevaccine shedding

Substanzen

Ebola VaccinesAntibodies, ViralViral Envelope ProteinsVaccines, SyntheticVaccines, Attenuated

Autor:innen und Institutionen

  • Merck & Co., Inc., Rahway, New Jersey, USA.
  • Inserm, CHU Bordeaux, CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, University of Bordeaux, Bordeaux, France.
  • Partnership for Research on Ebola Vaccines in Liberia (PREVAIL), Monrovia, Liberia.
  • Advanced BioMedical Laboratories (ABML), Cinnaminson, New Jersey, USA.
  • Pôle Recherche Clinique, Institut National de la Santé et de la Recherche Médicale (Inserm), Paris, France.
  • University Clinical Research Center (UCRC), Bamako, Mali.

Förderung

  • ASPR HHS
  • National Institutes of Health
  • (NIH)
  • Institut national de la santé et de la recherche médicale
  • London School of Hygiene and Tropical Medicine
  • Merck Sharp & Dohme LLC
  • Merck & Co., Inc.
  • Janssen

Zitieren

APA

Lee, A. W., Liu, K., Lhomme, E., Blie, J., McCullough, J., Onorato, M. T., Connor, L., Simon, J. K., Dubey, S., VanRheenen, S., Deutsch, J., Owens, A., Morgan, A., Welebob, C., Hyatt, D., Nair, S., Hamzé, B., Guindo, O., Sow, S. O., …, & PREVAC Study Team (2024). Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad693

Vancouver

Lee AW, Liu K, Lhomme E, Blie J, McCullough J, Onorato MT, et al. Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciad693

BibTeX
@article{Lee2024,
  author = {Lee, Andrew W and Liu, Ken and Lhomme, Edouard and Blie, Julie and McCullough, John and Onorato, Matthew T and Connor, Laurie and Simon, Jakub K and Dubey, Sheri and VanRheenen, Susan and Deutsch, Jonathan and Owens, Abigail and Morgan, Amy and Welebob, Carolee and Hyatt, Donna and Nair, Sunita and Hamzé, Benjamin and Guindo, Oumar and Sow, Samba O and Beavogui, Abdoul H and Leigh, Bailah and Samai, Mohamed and Akoo, Pauline and Serry-Bangura, Alimamy and Fleck, Suzanne and Secka, Fatou and Lowe, Brett and Watson-Jones, Deborah and Roy, Céline and Hensley, Lisa E and Kieh, Mark and Coller, Beth-Ann G and PREVAC Study Team, PREVAC Study Team},
  title = {Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciad693}
}
Kostenlos starten →